Bone Biologics Co. (OTC:BBLG – Get Free Report) rose 13% during trading on Friday . The company traded as high as $1.19 and last traded at $1.11. Approximately 375,913 shares changed hands during trading, an increase of 41% from the average daily volume of 265,956 shares. The stock had previously closed at $0.98.
Bone Biologics Price Performance
The firm has a market cap of $2.77 million, a price-to-earnings ratio of -0.02 and a beta of 0.45. The business’s 50-day moving average price is $1.19 and its two-hundred day moving average price is $1.45.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- What Makes a Stock a Good Dividend Stock?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- What is the Nikkei 225 index?
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Why is the Ex-Dividend Date Significant to Investors?
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
